Literature DB >> 18790932

Prognostic factors for multiple myeloma in the era of novel agents.

J Bladé1, L Rosiñol, M T Cibeira.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18790932     DOI： 10.1093/annonc/mdn437

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  10 in total

Review 1.  Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors:  Sean T Duggan; Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Authors:  Lesley J Scott; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

3.  Distinct Clinical Features of Plasma Cell Myeloma Patients Exhibiting Dysmorphic Plasma Cells: Association with More Plasma Cells at Diagnosis.

Authors:  Sang Hyuk Park; Joseph Jeong; Seon-Ho Lee; Yunsuk Choi; Jae-Cheol Jo; Ji-Hun Lim
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-15       Impact factor: 0.900

Review 4.  Pomalidomide: a review of its use in patients with recurrent multiple myeloma.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

5.  Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.

Authors:  Hua Wang; Liang Wang; Yue Lu; Xiaoqin Chen; Qirong Geng; Weida Wang; Zhongjun Xia
Journal:  Onco Targets Ther       Date:  2016-01-28       Impact factor: 4.147

6.  Clinicopathological significance of the p16 hypermethylation in multiple myeloma, a systematic review and meta-analysis.

Authors:  Huiqing Yu; Liejun Yang; Yunfeng Fu; Meng Gao; Ling Tian
Journal:  Oncotarget       Date:  2017-06-27

7.  Prevalence of p16 methylation and prognostic factors in plasma cell myeloma at a single institution in Korea.

Authors:  Hyunjung Kim; Dong Wook Jekarl; Myungshin Kim; Yonggoo Kim; Jihyang Lim; Kyungja Han; Chang-Ki Min
Journal:  Ann Lab Med       Date:  2012-12-17       Impact factor: 3.464

8.  The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.

Authors:  Jingsong He; Li Yang; Xiaoyan Han; Gaofeng Zheng; Weiyan Zheng; Guoqing Wei; Wenjun Wu; Xiujin Ye; Jimin Shi; Wanzhuo Xie; Li Li; Jie Zhang; Weijia Huang; Yi Zhao; He Huang; Xuejin Zhang; Jiaping Fu; Zhen Cai
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

9.  Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.

Authors:  David C Johnson; Niels Weinhold; Jonathan S Mitchell; Bowang Chen; Martin Kaiser; Dil B Begum; Jens Hillengass; Uta Bertsch; Walter A Gregory; David Cairns; Graham H Jackson; Asta Försti; Jolanta Nickel; Per Hoffmann; Markus M Nöethen; Owen W Stephens; Bart Barlogie; Faith E Davis; Kari Hemminki; Hartmut Goldschmidt; Richard S Houlston; Gareth J Morgan
Journal:  Nat Commun       Date:  2016-01-08       Impact factor: 14.919

10.  An interactive nomogram based on clinical and molecular signatures to predict prognosis in multiple myeloma patients.

Authors:  Linxin Liu; Jian Qu; Yuxin Dai; Tingting Qi; Xinqi Teng; Guohua Li; Qiang Qu
Journal:  Aging (Albany NY)       Date:  2021-07-14       Impact factor: 5.682
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.